Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLA2G4A | P47712 | 5/20 | 0.73 |
| ▸ | CYSLTR2 | Q9NS75 | 4/20 | 0.73 |
| ▸ | CYSLTR1 | Q9Y271 | 4/20 | 0.73 |
| ▸ | MEN1 | O00255 | 1/20 | 0.73 |
| ▸ | PTGES | O14684 | 1/20 | 0.73 |
| ▸ | XPO1 | O14980 | 1/20 | 0.73 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.73 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.73 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.73 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.73 |
| ▸ | EGFR | P00533 | 1/20 | 0.73 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.73 |
| ▸ | PGR | P06401 | 1/20 | 0.73 |
| ▸ | POLB | P06746 | 1/20 | 0.73 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.73 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.73 |
| ▸ | MAPT | P10636 | 1/20 | 0.73 |
| ▸ | RARB | P10826 | 1/20 | 0.73 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.73 |
| ▸ | CNR1 | P21554 | 1/20 | 0.73 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| N-Dealkylated Derivative SCHEMBL14862820 | 0.88 | CYSLTR2 (0.83) | PLA2G4ACYSLTR2CYSLTR1MEN1PTGES | |
| SCHEMBL4150784 | 0.86 | PLA2G4A (0.80) | PLA2G4ACYSLTR2CYSLTR1MEN1PTGES | |
| Zafirlukast SCHEMBL30885065 | 0.84 | PLA2G4A (1.00) | PLA2G4ACYSLTR2CYSLTR1MEN1PTGES | |
| Zafirlukast SCHEMBL29861631 | 0.84 | PLA2G4A (1.00) | PLA2G4ACYSLTR2CYSLTR1MEN1PTGES | |
| Zafirlukast SCHEMBL4175 | 0.84 | PLA2G4A (1.00) | PLA2G4ACYSLTR2CYSLTR1MEN1PTGES | |
| Zafirlukast SCHEMBL6600322 | 0.84 | PLA2G4A (1.00) | PLA2G4ACYSLTR2CYSLTR1MEN1PTGES | |
| Zafirlukast SCHEMBL29372773 | 0.84 | PLA2G4A (1.00) | PLA2G4ACYSLTR2CYSLTR1MEN1PTGES | |
| Zafirlukast SCHEMBL6381072 | 0.84 | PLA2G4A (0.99) | PLA2G4ACYSLTR2CYSLTR1MEN1PTGES | |
| Zafirlukast SCHEMBL6378803 | 0.84 | PLA2G4A (0.99) | PLA2G4ACYSLTR2CYSLTR1MEN1PTGES | |
| Zafirlukast SCHEMBL4586973 | 0.84 | PLA2G4A (0.99) | PLA2G4ACYSLTR2CYSLTR1MEN1PTGES |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140349969-A1 | COMPOUNDS AND METHODS FOR TREATING PAIN | AKRON MOLECULES AG (AT) | 2014-11-27 | — | — | US | disclosed |
| EP-2674161-A1 | FMO3 inhibitors for treating pain | Akron Molecules GmbH (AT) | 2013-12-18 | — | — | EP | disclosed |
| US-20130252924-A1 | Compounds and Methods for Treating Pain | AKRON MOLECULES GMBH (AT) | 2013-09-26 | — | — | US | disclosed |
| EP-2637649-A2 | COMPOUNDS AND METHODS FOR TREATING PAIN | Akron Molecules GmbH (AT) | 2013-09-18 | — | — | EP | disclosed |
| WO-2012062925-A2 | COMPOUNDS AND METHODS FOR TREATING PAIN | AKRON MOLECULES GMBH (AT) | 2012-05-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140349969-A1 | COMPOUNDS AND METHODS FOR TREATING PAIN | TRPV1, ACHE, OPRL1 | PLA2G4A 315/4885CYSLTR2 14/4885CYSLTR1 23/4885 |
| US-20130252924-A1 | Compounds and Methods for Treating Pain | TRPV1, ACHE, OPRL1 | PLA2G4A 315/4885CYSLTR2 14/4885CYSLTR1 23/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.